EVQLV, Manhattan BioSolutions Enter Strategic Collaboration to Discover Novel Antibody Therapies

Aug 25, 2020 | News, Press Releases | 0 comments

EVQLV

EVQLV, Inc., an artificial intelligence-enabled technology company accelerating biologics discovery, announced today a strategic research collaboration with Manhattan BioSolutions, Inc., a biotechnology company focused on developing next-generation therapies for cancer and inflammatory diseases. Through the collaboration, the companies will jointly discover differentiated antibody therapeutics for oncology indications.  This collaboration combines EVQLV’s expertise in AI-enabled antibody design with Manhattan BioSolutions’ expertise in development of novel oncology medicines.

Under the terms of the agreement, EVQLV will use its proprietary AI platform to computationally generate, rapidly screen and optimize fully-human antibodies against select targets. Manhattan BioSolutions will further advance the AI-design antibodies into preclinical studies.

In addition to the collaboration, Boris Shor, PhD, CEO of Manhattan BioSolutions, has joined EVQLV’s Scientific Advisory Board.

“We believe AI technology developed by EVQLV can enable efficient antibody design with dramatically shorter therapeutic discovery timelines,” said Dr. Boris Shor. “This also represents an exciting approach to generate functionally diverse antibody candidates with unique properties or mechanisms of action. This agreement aligns with our focus on novel therapies at the intersection of innate immunity, cancer and age-related diseases.”

Dr. Shor’s years of experience at large pharma and his keen understanding of the intricacies of biologics discovery/development will have an immediate impact on our organization,” says Andrew Satz, CEO of EVQLV. “We are excited by the collaboration along with the vision and experience Dr. Shor contributes to our team as we continue to build technology that bridges the gap between science and tech.”

About EVQLV

EVQLV develops artificial intelligence, engineered with life science data and biological knowledge, to accelerate the speed at which biologic therapies reach patients. Comprised of experts in machine learning, molecular biology, computational biology, software engineering, bioinformatics, antibody design, cloud computing, and preclinical/clinical development, EVQLV is on a mission to transform how healing reaches those in need. For further information, visit www.evqlv.com

EVQLV Contact: Andrew Satz ([email protected])

About Manhattan BioSolutions

Manhattan BioSolutions, Inc (MBS) is a privately held biotechnology company focused on the discovery and development of immunotherapies that target innate immunity for the treatment of cancer and inflammatory diseases. MBS leverages two technology platforms for drug discovery: microbial based genetically engineered immune stimulator platform, and monoclonal antibodies against innate immune sensors that recognize pathogens or endogenous “danger signals” released as a result of tissue injury or inflammation.

Manhattan BioSolutions Contact: Boris Shor, PhD ([email protected])

0 Comments

Submit a Comment

Your email address will not be published. Required fields are marked *

NY Bio-Computation Startup EVQLV Closes Financing Round

NEW YORK, February 8, 2021 -- EVQLV, an innovator in developing artificial intelligence to accelerate how biologic therapies reach patients, today announced the closing of a funding round that will be used to advance the company’s R&D efforts, boost development...

EVQLV Welcomes Operations & Finance Lead Alexander Sonneborn

NEW YORK, February 1, 2021 -- EVQLV is pleased to announce that Alexander Sonneborn has joined EVQLV to oversee company operations and finances. After an early career in the life sciences, Alexander transitioned to entrepreneurial activities in technology-based...

EVQLV Submits 1 Million Ab Initio Derived Sequences for Validation

NEW YORK, January 12, 2021 - EVQLV has submitted one million AI-generated sequences for independent laboratory validation in fulfillment of the second phase of a project with its collaborator. The first phase of the project consisted of 100 antibody sequences based...

Fully Automated Rabbit Humanization Project Initiated w/ U Buffalo

NEW YORK, December 16, 2020 -- EVQLV is eagerly anticipating the results from the second phase of their University at Buffalo rabbit-humanization collaboration. Starting with rabbit monoclonal antibodies, EVQLV is attempting to validate its fully-automated...

EVQLV Accepted to Prestigious Techstars Boston Accelerator

NEW YORK, November 18, 2020 -- EVQLV, a New York company that uses AI to accelerate the development of antibodies, will be one of 10 startups in the new class of the Techstars Boston program. This year’s program will be 100% virtual and, for the first time, will...

Pin It on Pinterest